Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.
Study Start Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy male or female subjects aged 18 to 45 years, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests
Vital signs within the following ranges:
oral body temperature 35.0 - 37.5°C
systolic blood pressure 90 - 140 mm Hg
diastolic blood pressure 50 - 90 mm Hg
pulse rate 40 - 90 bpm
Female subjects of child bearing potential must be using double-barrier local contraception (for example, intra-uterine device plus condom, or spermicidal gel plus condom) or have been surgically sterilized at least 6 months prior before study start, with supportive clinical documentation OR Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion.
Body mass index must be within 18 - 30 kg/m2. Subjects must weigh at least 50 kg.
Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as those who report tobacco use or have a urine cotinine greater than 500 ng/mL
Female subjects who are pregnant or lactating
Participation in any clinical investigation involving medical intervention within 4 week prior to study start.
Donation or loss of ≥ 400 mL of blood within 8 weeks prior to study start, or longer if required by local regulation.
Significant illness within 2 weeks before study start.
A past personal or close family medical history of clinically significant ECG abnormalities or of a prolonged QT-interval syndrome.
History of autonomic dysfunction (for example, history of fainting).
History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or untreated),
History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or to similar drugs.
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, or which may jeopardize the subject in case of participation in the study, including bowel, gastrointestinal, renal, pancreatic, hepatic, hematological, immunological, or neurological disorders.
Other protocol-defined inclusion/exclusion criteria may apply